NCT01942460

Ferumoxytol for Iron-Deficiency Anemia in Chronic Kidney Disease and Peritoneal Dialysis Patients

Use of FERAHEME® (Ferumoxytol) for Severe Chronic Kidney Disease and Peritoneal Dialysis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Georges Ouellet · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the efficacy of ferumoxytol for the repletion of iron stores and correction of iron deficiency anaemia in patients with severe chronic kidney disease or end-stage chronic kidney disease on peritoneal dialysis, and to assess the impact of the administration of a ferumoxytol dose on various markers for iron stores, as well as on various markers for inflammation and oxidative stress.

Conditions

• Iron-Deficiency Anemia
• Inflammation
• Oxidative Stress

Interventions

Type	Name	Description
DRUG	Ferumoxytol

Timeline

• Start date: 2013-09-01
• Primary completion: 2014-05-01
• Completion: 2014-06-01
• First posted: 2013-09-16
• Last updated: 2015-04-13

Locations

1 site across 1 country: Canada